Soleno Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Soleno Therapeutics

07/05/2025 22:06

Soleno Therapeutics Inc SLNO.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -59 cents.  The mean expectation of nine analysts for the quarter was for a loss of 93 cents per share. Wall Street expected results to range from $-1.43 to -66 cents per share.

Reported revenue was zero​; analysts expected zero.

Soleno Therapeutics Inc's reported EPS for the quarter was a loss of 95 cents​.

The company reported a quarterly loss of $43.77 million.

Soleno Therapeutics Inc shares had risen by 3.2% this quarter and gained 64.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 23.3% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Soleno Therapeutics Inc is $105.00

This summary was machine generated from LSEG data May 7 at 09:06 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.93
-0.95
Missed
Dec. 31 2024
-1.15
-1.27
Missed
Sep. 30 2024
-0.63
-1.83
Missed
Jun. 30 2024
-0.60
-0.57
Beat